FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1630482321> ?p ?o ?g. }

• W1630482321 endingPage "694" @default.
• W1630482321 startingPage "686" @default.
• W1630482321 abstract "Activating FGFR2 mutations are found in 10-16% of primary endometrial cancers and provide an opportunity for targeted therapy. We assessed the safety and activity of dovitinib, a potent tyrosine-kinase inhibitor of fibroblast growth factor receptors, VEGF receptors, PDGFR-β, and c-KIT, as second-line therapy both in patients with FGFR2-mutated (FGFR2(mut)) endometrial cancer and in those with FGFR2-non-mutated (FGFR2(non-mut)) endometrial cancer.In this phase 2, non-randomised, two-group, two-stage study, we enrolled adult women who had progressive disease after first-line chemotherapy for advanced or metastatic endometrial cancer from 46 clinical sites in seven countries. We grouped women according to FGFR2 mutation status and gave all women dovitinib (500 mg per day, orally, on a 5-days-on and 2-days-off schedule) until disease progression, unacceptable toxicity, death, or study discontinuation for any other reason. The primary endpoint was proportion of patients in each group who were progression-free at 18 weeks. For each group, the second stage of the trial (enrolment of 20 additional patients) could proceed if at least eight of the first 20 treated patients were progression free at 18 weeks. Activity was assessed in all enrolled patients and safety was assessed in all patients who received at least one dose of dovitinib. The completed study is registered with ClinicalTrials.gov, number NCT01379534.Of 248 patients with FGFR2 prescreening results, 27 (11%) had FGFR2(mut) endometrial cancer. Between Feb 17, 2012, and Dec 13, 2013, we enrolled 22 patients in the FGFR2(mut) group and 31 patients in the FGFR2(non-mut) group. Seven (31·8%, 95% CI 13·9-54·9) patients in the FGFR2(mut) group and nine (29·0%, 14·2-48·0) in the FGFR2(non-mut) group were progression-free at 18 weeks. On the basis of predefined criteria, neither group continued to stage two: seven (35%) of the first 20 patients in the FGFR2(mut) group were progression free at 18 weeks, as were five (25%) of the first 20 in the FGFR2(mut) population. Rates of treatment-emergent adverse events were similar between groups and events were most frequently gastrointestinal. Overall, the most common grade 3 or 4 adverse events suspected to be related to the study drug were hypertension (nine patients; 17%) and diarrhoea (five; 9%). The most frequently reported serious adverse events suspected to be related to study drug were pulmonary embolism (four patients; 8%), vomiting (four; 8%), dehydration (three; 6%), and diarrhoea (three; 6%). Only one death was deemed to be treatment-related: one patient in the FGFR2(non-mut) group died from cardiac arrest with contributing reason of pulmonary embolism (grade 4, suspected to be study drug related) 4 days previously.Second-line dovitinib in FGFR2(mut) and FGFR2(non-mut) advanced or metastatic endometrial cancer had single-agent activity, although it did not reach the prespecified study criteria. Observed treatment effects seemed independent of FGFR2 mutation status. These data should be considered exploratory and additional studies are needed.Novartis Pharmaceuticals." @default.
• W1630482321 created "2016-06-24" @default.
• W1630482321 creator A5023802024 @default.
• W1630482321 creator A5029475800 @default.
• W1630482321 creator A5031295518 @default.
• W1630482321 creator A5039043075 @default.
• W1630482321 creator A5042371948 @default.
• W1630482321 creator A5042614329 @default.
• W1630482321 creator A5052405727 @default.
• W1630482321 creator A5056423529 @default.
• W1630482321 creator A5061939825 @default.
• W1630482321 creator A5062837404 @default.
• W1630482321 creator A5071585351 @default.
• W1630482321 creator A5088144652 @default.
• W1630482321 date "2015-06-01" @default.
• W1630482321 modified "2023-10-13" @default.
• W1630482321 title "Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study" @default.
• W1630482321 cites W1905382513 @default.
• W1630482321 cites W1970614336 @default.
• W1630482321 cites W1970714443 @default.
• W1630482321 cites W1971138161 @default.
• W1630482321 cites W1971340381 @default.
• W1630482321 cites W1975704460 @default.
• W1630482321 cites W2019607817 @default.
• W1630482321 cites W2041440766 @default.
• W1630482321 cites W2050325895 @default.
• W1630482321 cites W2059983371 @default.
• W1630482321 cites W2075790601 @default.
• W1630482321 cites W2088947243 @default.
• W1630482321 cites W2089756110 @default.
• W1630482321 cites W2091022821 @default.
• W1630482321 cites W2096055270 @default.
• W1630482321 cites W2098320019 @default.
• W1630482321 cites W2108353976 @default.
• W1630482321 cites W2109023930 @default.
• W1630482321 cites W2118471405 @default.
• W1630482321 cites W2123312554 @default.
• W1630482321 cites W2127385754 @default.
• W1630482321 cites W2141416577 @default.
• W1630482321 cites W2146807741 @default.
• W1630482321 cites W2154516141 @default.
• W1630482321 cites W2160981405 @default.
• W1630482321 cites W2164185692 @default.
• W1630482321 cites W2164553702 @default.
• W1630482321 cites W2167264978 @default.
• W1630482321 cites W2334202689 @default.
• W1630482321 doi "https://doi.org/10.1016/s1470-2045(15)70159-2" @default.
• W1630482321 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25981814" @default.
• W1630482321 hasPublicationYear "2015" @default.
• W1630482321 type Work @default.
• W1630482321 sameAs 1630482321 @default.
• W1630482321 citedByCount "75" @default.
• W1630482321 countsByYear W16304823212015 @default.
• W1630482321 countsByYear W16304823212016 @default.
• W1630482321 countsByYear W16304823212017 @default.
• W1630482321 countsByYear W16304823212018 @default.
• W1630482321 countsByYear W16304823212019 @default.
• W1630482321 countsByYear W16304823212020 @default.
• W1630482321 countsByYear W16304823212021 @default.
• W1630482321 countsByYear W16304823212022 @default.
• W1630482321 countsByYear W16304823212023 @default.
• W1630482321 crossrefType "journal-article" @default.
• W1630482321 hasAuthorship W1630482321A5023802024 @default.
• W1630482321 hasAuthorship W1630482321A5029475800 @default.
• W1630482321 hasAuthorship W1630482321A5031295518 @default.
• W1630482321 hasAuthorship W1630482321A5039043075 @default.
• W1630482321 hasAuthorship W1630482321A5042371948 @default.
• W1630482321 hasAuthorship W1630482321A5042614329 @default.
• W1630482321 hasAuthorship W1630482321A5052405727 @default.
• W1630482321 hasAuthorship W1630482321A5056423529 @default.
• W1630482321 hasAuthorship W1630482321A5061939825 @default.
• W1630482321 hasAuthorship W1630482321A5062837404 @default.
• W1630482321 hasAuthorship W1630482321A5071585351 @default.
• W1630482321 hasAuthorship W1630482321A5088144652 @default.
• W1630482321 hasBestOaLocation W16304823212 @default.
• W1630482321 hasConcept C121608353 @default.
• W1630482321 hasConcept C126322002 @default.
• W1630482321 hasConcept C143998085 @default.
• W1630482321 hasConcept C203092338 @default.
• W1630482321 hasConcept C2776694085 @default.
• W1630482321 hasConcept C2777088508 @default.
• W1630482321 hasConcept C2778715236 @default.
• W1630482321 hasConcept C2778822529 @default.
• W1630482321 hasConcept C31760486 @default.
• W1630482321 hasConcept C535046627 @default.
• W1630482321 hasConcept C71924100 @default.
• W1630482321 hasConcept C90924648 @default.
• W1630482321 hasConceptScore W1630482321C121608353 @default.
• W1630482321 hasConceptScore W1630482321C126322002 @default.
• W1630482321 hasConceptScore W1630482321C143998085 @default.
• W1630482321 hasConceptScore W1630482321C203092338 @default.
• W1630482321 hasConceptScore W1630482321C2776694085 @default.
• W1630482321 hasConceptScore W1630482321C2777088508 @default.
• W1630482321 hasConceptScore W1630482321C2778715236 @default.
• W1630482321 hasConceptScore W1630482321C2778822529 @default.
• W1630482321 hasConceptScore W1630482321C31760486 @default.
• W1630482321 hasConceptScore W1630482321C535046627 @default.
• W1630482321 hasConceptScore W1630482321C71924100 @default.

• next